Moderna to Supply Up to 500 Million Vaccine Doses to Covax
(Bloomberg) -- Moderna Inc. agreed to provide as many as 500 million doses of its Covid-19 shot to the program known as Covax in a boost for the global vaccination effort, but only a small fraction of the shipments are due to arrive this year.
The U.S. drugmaker is joining developers including AstraZeneca Plc, Pfizer Inc. and Johnson & Johnson in supplying Covax, which has faced setbacks in its bid to help lower-income nations. The vaccine last week was cleared for emergency use by the World Health Organization, making it eligible for Covax.
Covax has encountered funding challenges, delivery delays and other hurdles in a high-stakes campaign to narrow the vaccine-access gap. As India confronts a devastating resurgence of the illness, concerns are rising for many countries around the world that have been left behind their wealthier counterparts.
Rich countries last year snapped up vaccine supplies from Moderna and others, and the U.S. alone has already administered more than 240 million doses. Covax meanwhile has shipped about 50 million to more than 120 countries and territories, based on data through late April.
More Than 1.16 Billion Shots Given: Covid-19 Vaccine Tracker
Supplies of Moderna's messenger RNA vaccine to Covax are set to begin in the fourth quarter, with 34 million doses available in 2021, according to Gavi, the Vaccine Alliance, one of the partners in the initiative.
The U.S. drugmaker will supply as many as 466 million doses in 2022 and potentially provide access to shots that are adapted to fight virus variants in the future. Moderna CEO Stephane Bancel last week said he was deeply worried about variant-driven epidemics in places like South America and India.
The terms of the agreement with Gavi weren't disclosed, though Moderna said it's offering the vaccine at the company's “lowest-tiered price.”
Variant Risks
The doses will help broaden Covax's portfolio. The program is heavily reliant on the Astra shot, which is cheaper and easier to deploy but has faced worries about rare blood clots that have complicated immunization campaigns. Covax is also leaning on the Serum Institute of India Ltd. as a key supplier, but the country said in March it would slow down exports to focus on its own needs.
“Having a diverse portfolio has always been a core goal for Covax, and to remain adaptable in the face of this continually evolving pandemic -- including the rising threat posed by new variants,” Gavi Chief Executive Officer Seth Berkley said Monday.
Gavi has said it's seeking to raise $2 billion by June to secure additional doses to cover as much as 30% of the populations in 92 lower-income economies. Covax is led by Gavi, the WHO and the Coalition for Epidemic Preparedness Innovations, and works with organizations including UNICEF as well. Sweden also pledged to donate 1 million doses of the Astra and University of Oxford vaccine, Gavi said.
Pfizer and BioNTech SE in January agreed to supply as many as 40 million doses to Covax, which is also due to receive up to 500 million doses of J&J's single-shot vaccine.
While Astra has pledged not to profit from its vaccine during the pandemic and recorded $275 million in sales from the shot in the first quarter, Moderna has said it expects to bring in more than $18 billion in Covid vaccine sales this year.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.